beta

CYAD

Celyad SA

Cyad

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Celyad SA is a biopharmaceutical company. The company is engaged in stem cell-based therapies for the treatment of cardiovascular diseases. It is developing therapeutic therapies based on two distinct technology platforms in cardiology and oncology.

Market Cap: 467 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.celyad.com

Shares Outstanding: 9.86 Million

Float: 9.86 Million

Dividend: 0.0 (0.0%)

Beta: 1.314406

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 82.8 Thousand

Ethical Flags

Animal testing

Longest drawdown: 679 trading days

From: 2017-10-05 To: 2019-06-12

Lowest Point:

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad SA (CYAD) CEO Christian Homsy on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-29 10:30:08:000

Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a… read more...

Celyad reports FY results

via: SeekingAlpha at 2019-03-28 12:10:26:000

Celyad (NASDAQ: CYAD ): FY GAAP EPS of -3.36. More news on: Celyad SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 08:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

Bellicum: Oversold In 2018 And Undervalued 2019

via: SeekingAlpha at 2019-01-22 03:11:23:000

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related… read more...

FDA to beef up cell and gene therapy staff

via: SeekingAlpha at 2019-01-15 13:17:05:000

Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...

FDA to beef up cell and gene therapy staff

via: SeekingAlpha at 2019-01-15 13:17:05:000

Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...

FDA to beef up cell and gene therapy staff

via: SeekingAlpha at 2019-01-15 13:17:05:000

Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...

Celyad announces key 2019 priorities

via: SeekingAlpha at 2019-01-07 08:03:54:000

Celyad (NASDAQ: CYAD ) provides clinical update on CYAD-01 and CYAD-101 with key upcoming milestones for 2019. More news on: Celyad, Healthcare stocks news, Read more … read more...

Celyad announces key 2019 priorities

via: SeekingAlpha at 2019-01-07 08:03:54:000

Celyad (NASDAQ: CYAD ) provides clinical update on CYAD-01 and CYAD-101 with key upcoming milestones for 2019. More news on: Celyad, Healthcare stocks news, Read more … read more...

Celyad announces key 2019 priorities

via: SeekingAlpha at 2019-01-07 08:03:54:000

Celyad (NASDAQ: CYAD ) provides clinical update on CYAD-01 and CYAD-101 with key upcoming milestones for 2019. More news on: Celyad, Healthcare stocks news, Read more … read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Positive early-stage data on Celyad's lead candidate fails to lift shares, down 8%

via: SeekingAlpha at 2018-12-04 12:50:21:000

Ultra-thinly traded Celyad ( CYAD -8.2% ) is down on average volume, only 5,129 shares, despite its announcement of encouraging results from a Phase 1 dose-escalation clinical trial, THINK , evaluating lead CAR-T candidate CYAD-01 without preconditioning chemo in patients with solid tum… read more...

Celyad doses first mCRC patient in the Phase 1 alloSHRINK trial

via: SeekingAlpha at 2018-11-30 06:51:57:000

Celyad (NASDAQ: CYAD ) announces the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the Companys non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastat… read more...

Celyad doses first mCRC patient in the Phase 1 alloSHRINK trial

via: SeekingAlpha at 2018-11-30 06:51:57:000

Celyad (NASDAQ: CYAD ) announces the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the Companys non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastat… read more...

Celyad doses first mCRC patient in the Phase 1 alloSHRINK trial

via: SeekingAlpha at 2018-11-30 06:51:57:000

Celyad (NASDAQ: CYAD ) announces the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the Companys non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastat… read more...

Celyad doses first mCRC patient in the Phase 1 alloSHRINK trial

via: SeekingAlpha at 2018-11-30 06:51:57:000

Celyad (NASDAQ: CYAD ) announces the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the Companys non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastat… read more...

Celyad: The Second Wave

via: SeekingAlpha at 2018-11-27 02:01:32:000

Celyad ( CYAD ) is trading back in the $25 zone, making it very appealing once again. There could be a variety of reasons for the stock to fall. If any of these reasons runs counter to Celyads investment thesis, then the low price would not be appealing. However, as we discuss here, de… read more...

Celyad: The Second Wave

via: SeekingAlpha at 2018-11-27 02:01:32:000

Celyad ( CYAD ) is trading back in the $25 zone, making it very appealing once again. There could be a variety of reasons for the stock to fall. If any of these reasons runs counter to Celyads investment thesis, then the low price would not be appealing. However, as we discuss here, de… read more...

Celyad: The Second Wave

via: SeekingAlpha at 2018-11-27 02:01:32:000

Celyad ( CYAD ) is trading back in the $25 zone, making it very appealing once again. There could be a variety of reasons for the stock to fall. If any of these reasons runs counter to Celyads investment thesis, then the low price would not be appealing. However, as we discuss here, de… read more...

Celyad +7% as lead CAR-T drug candidate shows no toxicity in safety tests

via: SeekingAlpha at 2018-11-21 15:08:22:000

Celyad ( CYAD +7.2% ) surges after disclosing the first patient treated with its CYAD-101 drug candidate showed no toxicity during a safety and anti-tumor activity study of its lead non-gene edited, allogeneic CAR-T clinical candidate. More news on: Celyad, Healthcare stocks news, Stoc… read more...

Celyad +7% as lead CAR-T drug candidate shows no toxicity in safety tests

via: SeekingAlpha at 2018-11-21 15:08:22:000

Celyad ( CYAD +7.2% ) surges after disclosing the first patient treated with its CYAD-101 drug candidate showed no toxicity during a safety and anti-tumor activity study of its lead non-gene edited, allogeneic CAR-T clinical candidate. More news on: Celyad, Healthcare stocks news, Stoc… read more...

Celyad +7% as lead CAR-T drug candidate shows no toxicity in safety tests

via: SeekingAlpha at 2018-11-21 15:08:22:000

Celyad ( CYAD +7.2% ) surges after disclosing the first patient treated with its CYAD-101 drug candidate showed no toxicity during a safety and anti-tumor activity study of its lead non-gene edited, allogeneic CAR-T clinical candidate. More news on: Celyad, Healthcare stocks news, Stoc… read more...

Celyad announces exclusive agreement for Horizon Discovery's shRNA platform

via: SeekingAlpha at 2018-10-04 07:04:20:000

Celyad(NASDAQ: CYAD ) announces an exclusive agreement with Horizon Discovery Group ( OTC:HZNQF ), for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. More news on: Celyad, HORIZONS DISCOVERY GP ORD, Healthcare stocks news, Read more… read more...

Celyad announces exclusive agreement for Horizon Discovery's shRNA platform

via: SeekingAlpha at 2018-10-04 07:04:20:000

Celyad(NASDAQ: CYAD ) announces an exclusive agreement with Horizon Discovery Group ( OTC:HZNQF ), for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. More news on: Celyad, HORIZONS DISCOVERY GP ORD, Healthcare stocks news, Read more… read more...

Celyad announces exclusive agreement for Horizon Discovery's shRNA platform

via: SeekingAlpha at 2018-10-04 07:04:20:000

Celyad(NASDAQ: CYAD ) announces an exclusive agreement with Horizon Discovery Group ( OTC:HZNQF ), for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. More news on: Celyad, HORIZONS DISCOVERY GP ORD, Healthcare stocks news, Read more… read more...

Celyad announces exclusive agreement for Horizon Discovery's shRNA platform

via: SeekingAlpha at 2018-10-04 07:04:20:000

Celyad(NASDAQ: CYAD ) announces an exclusive agreement with Horizon Discovery Group ( OTC:HZNQF ), for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. More news on: Celyad, HORIZONS DISCOVERY GP ORD, Healthcare stocks news, Read more… read more...

Celyad announces exclusive agreement for Horizon Discovery's shRNA platform

via: SeekingAlpha at 2018-10-04 07:04:20:000

Celyad(NASDAQ: CYAD ) announces an exclusive agreement with Horizon Discovery Group ( OTC:HZNQF ), for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. More news on: Celyad, HORIZONS DISCOVERY GP ORD, Healthcare stocks news, Read more… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data

via: SeekingAlpha at 2018-08-24 20:37:24:000

Shares of Belgium-based biotech firm Celyad ( CYAD ) have fallen by nearly 60% since its IPO was priced back in 2015. Year-to-date the stock has lost nearly a third of its value. Founded in 2007, the firm also has a base in New York and shares are listed on both Euronext Brussels and Euronex… read more...

Celyad reports 1H results

via: SeekingAlpha at 2018-08-23 05:51:27:000

Celyad (NASDAQ: CYAD ): 1H GAAP EPS of -1.79. More news on: Celyad, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Celyad reports 1H results

via: SeekingAlpha at 2018-08-23 05:51:27:000

Celyad (NASDAQ: CYAD ): 1H GAAP EPS of -1.79. More news on: Celyad, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Celyad Looks To Take The Cake In Speculative Biotech

via: SeekingAlpha at 2018-07-30 14:53:05:000

Author's note: I am an affiliate of Avisol Capital Partners' Total Pharma Tracker . Although we have a business relationship, Avisol Capital Partners' coverage of Celyad on Seeking Alpha has not in any way informed my writing of this article, except for the mention of their article from … read more...

Celyad Looks To Take The Cake In Speculative Biotech

via: SeekingAlpha at 2018-07-30 14:53:05:000

Author's note: I am an affiliate of Avisol Capital Partners' Total Pharma Tracker . Although we have a business relationship, Avisol Capital Partners' coverage of Celyad on Seeking Alpha has not in any way informed my writing of this article, except for the mention of their article from … read more...

Celyad Looks To Take The Cake In Speculative Biotech

via: SeekingAlpha at 2018-07-30 14:53:05:000

Author's note: I am an affiliate of Avisol Capital Partners' Total Pharma Tracker . Although we have a business relationship, Avisol Capital Partners' coverage of Celyad on Seeking Alpha has not in any way informed my writing of this article, except for the mention of their article from … read more...

3 Things In Biotech, July 25: A Chinese Blitz Continues

via: SeekingAlpha at 2018-07-25 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. BeiGene launches two big studies Company: BeiGene ( BGNE ) and Celgene ( CELG ) Thera… read more...

3 Things In Biotech, July 25: A Chinese Blitz Continues

via: SeekingAlpha at 2018-07-25 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. BeiGene launches two big studies Company: BeiGene ( BGNE ) and Celgene ( CELG ) Thera… read more...

3 Things In Biotech, July 25: A Chinese Blitz Continues

via: SeekingAlpha at 2018-07-25 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. BeiGene launches two big studies Company: BeiGene ( BGNE ) and Celgene ( CELG ) Thera… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

First AML patient dosed in early-stage study of Celyad's CYAD-01; shares up 3% premarket

via: SeekingAlpha at 2018-06-19 07:11:58:000

Thinly traded micro cap Celyad (NASDAQ: CYAD ) is up 3% premarket on light volume on the heels of its announcement that the first acute myeloid leukemia (AML) patient has been dosed at the third and final dose level in the blood cancer arm of its open-label Phase 1 THINK stud… read more...

First AML patient dosed in early-stage study of Celyad's CYAD-01; shares up 3% premarket

via: SeekingAlpha at 2018-06-19 07:11:58:000

Thinly traded micro cap Celyad (NASDAQ: CYAD ) is up 3% premarket on light volume on the heels of its announcement that the first acute myeloid leukemia (AML) patient has been dosed at the third and final dose level in the blood cancer arm of its open-label Phase 1 THINK stud… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-31 09:09:43:000

Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-31 09:09:43:000

Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-31 09:09:43:000

Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-25 08:37:29:000

Enanta Pharmaceuticals (NASDAQ: ENTA ) initiated with Outperform rating and $135 (38% upside) price target at Oppenheimer. More news on: Enanta Pharmaceuticals, Inc., Celyad, Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-25 08:37:29:000

Enanta Pharmaceuticals (NASDAQ: ENTA ) initiated with Outperform rating and $135 (38% upside) price target at Oppenheimer. More news on: Enanta Pharmaceuticals, Inc., Celyad, Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-25 08:37:29:000

Enanta Pharmaceuticals (NASDAQ: ENTA ) initiated with Outperform rating and $135 (38% upside) price target at Oppenheimer. More news on: Enanta Pharmaceuticals, Inc., Celyad, Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-25 08:37:29:000

Enanta Pharmaceuticals (NASDAQ: ENTA ) initiated with Outperform rating and $135 (38% upside) price target at Oppenheimer. More news on: Enanta Pharmaceuticals, Inc., Celyad, Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-25 08:37:29:000

Enanta Pharmaceuticals (NASDAQ: ENTA ) initiated with Outperform rating and $135 (38% upside) price target at Oppenheimer. More news on: Enanta Pharmaceuticals, Inc., Celyad, Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-25 08:37:29:000

Enanta Pharmaceuticals (NASDAQ: ENTA ) initiated with Outperform rating and $135 (38% upside) price target at Oppenheimer. More news on: Enanta Pharmaceuticals, Inc., Celyad, Novartis AG, Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions

via: SeekingAlpha at 2018-05-17 00:16:34:000

Analysis focus: BHVN Biohaven Pharmaceuticals (BHVN) is a CNS-focused company with a strong pipeline with multiple drug candidates in late stage trials. The company recently announced a number of updates for its pipeline. For its lead candidate, rimegepant from the CGRP receptor antagoni… read more...

Celyad -3.3% after announcing 1.8M-unit offering

via: SeekingAlpha at 2018-05-15 19:33:19:000

Clinical-stage biopharmaceutical firm Celyad (NASDAQ: CYAD ) is off 3.3% in U.S. trading after announcing a plan to sell 1.8M units in a global offering . More news on: Celyad, Healthcare stocks news, Stocks on the move, Read more … read more...

Celyad -3.3% after announcing 1.8M-unit offering

via: SeekingAlpha at 2018-05-15 19:33:19:000

Clinical-stage biopharmaceutical firm Celyad (NASDAQ: CYAD ) is off 3.3% in U.S. trading after announcing a plan to sell 1.8M units in a global offering . More news on: Celyad, Healthcare stocks news, Stocks on the move, Read more … read more...

Celyad -3.3% after announcing 1.8M-unit offering

via: SeekingAlpha at 2018-05-15 19:33:19:000

Clinical-stage biopharmaceutical firm Celyad (NASDAQ: CYAD ) is off 3.3% in U.S. trading after announcing a plan to sell 1.8M units in a global offering . More news on: Celyad, Healthcare stocks news, Stocks on the move, Read more … read more...

Celyad -3.3% after announcing 1.8M-unit offering

via: SeekingAlpha at 2018-05-15 19:33:19:000

Clinical-stage biopharmaceutical firm Celyad (NASDAQ: CYAD ) is off 3.3% in U.S. trading after announcing a plan to sell 1.8M units in a global offering . More news on: Celyad, Healthcare stocks news, Stocks on the move, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-11 12:02:27:000

Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-11 12:02:27:000

Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-11 12:02:27:000

Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-11 12:02:27:000

Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more … read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Dosing underway in early-stage studies of Celyad's CAR-T therapy CYAD-01

via: SeekingAlpha at 2018-05-03 09:17:38:000

Celyad (NASDAQ: CYAD ) announces that the first patients have been treated with lead candidate CYAD-01 in two early-stage studies and both appear to be tolerating the CAR-T therapy well. More news on: Celyad, Healthcare stocks news, Read more … read more...

Dosing underway in early-stage studies of Celyad's CAR-T therapy CYAD-01

via: SeekingAlpha at 2018-05-03 09:17:38:000

Celyad (NASDAQ: CYAD ) announces that the first patients have been treated with lead candidate CYAD-01 in two early-stage studies and both appear to be tolerating the CAR-T therapy well. More news on: Celyad, Healthcare stocks news, Read more … read more...

Dosing underway in early-stage studies of Celyad's CAR-T therapy CYAD-01

via: SeekingAlpha at 2018-05-03 09:17:38:000

Celyad (NASDAQ: CYAD ) announces that the first patients have been treated with lead candidate CYAD-01 in two early-stage studies and both appear to be tolerating the CAR-T therapy well. More news on: Celyad, Healthcare stocks news, Read more … read more...

Dosing underway in early-stage studies of Celyad's CAR-T therapy CYAD-01

via: SeekingAlpha at 2018-05-03 09:17:38:000

Celyad (NASDAQ: CYAD ) announces that the first patients have been treated with lead candidate CYAD-01 in two early-stage studies and both appear to be tolerating the CAR-T therapy well. More news on: Celyad, Healthcare stocks news, Read more … read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Midday Gainers / Losers (04/27/2018)

via: SeekingAlpha at 2018-04-27 12:45:34:000

Gainers : GNPX +36% . ENVA +27% . BOOM +24% . AQMS +20% . CYAD +19% . NVIV +17% . SIVB +16% . EHTH +16% . AQB +15% . KN +15% . More news on: Genprex, Inc, Enova International, Inc., DMC Global Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (04/27/2018)

via: SeekingAlpha at 2018-04-27 12:45:34:000

Gainers : GNPX +36% . ENVA +27% . BOOM +24% . AQMS +20% . CYAD +19% . NVIV +17% . SIVB +16% . EHTH +16% . AQB +15% . KN +15% . More news on: Genprex, Inc, Enova International, Inc., DMC Global Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (04/27/2018)

via: SeekingAlpha at 2018-04-27 12:45:34:000

Gainers : GNPX +36% . ENVA +27% . BOOM +24% . AQMS +20% . CYAD +19% . NVIV +17% . SIVB +16% . EHTH +16% . AQB +15% . KN +15% . More news on: Genprex, Inc, Enova International, Inc., DMC Global Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (04/27/2018)

via: SeekingAlpha at 2018-04-27 12:45:34:000

Gainers : GNPX +36% . ENVA +27% . BOOM +24% . AQMS +20% . CYAD +19% . NVIV +17% . SIVB +16% . EHTH +16% . AQB +15% . KN +15% . More news on: Genprex, Inc, Enova International, Inc., DMC Global Inc., Stocks on the move, , Read more … read more...

Celyad up 20% on encouraging data on CAR-T candidate CYAD-01

via: SeekingAlpha at 2018-04-27 11:27:11:000

Ultra-thinly traded micro cap Celyad ( CYAD +20.3% ) is up on almost a 10x surge in volume, albeit on turnover of only 26K shares, on the heels of its announcement of case data from a Phase 1 clinical trial, THINK , assessing lead CAR-T candidate CYAD-01 in patients with treatment-resis… read more...

Celyad up 20% on encouraging data on CAR-T candidate CYAD-01

via: SeekingAlpha at 2018-04-27 11:27:11:000

Ultra-thinly traded micro cap Celyad ( CYAD +20.3% ) is up on almost a 10x surge in volume, albeit on turnover of only 26K shares, on the heels of its announcement of case data from a Phase 1 clinical trial, THINK , assessing lead CAR-T candidate CYAD-01 in patients with treatment-resis… read more...

Celyad up 20% on encouraging data on CAR-T candidate CYAD-01

via: SeekingAlpha at 2018-04-27 11:27:11:000

Ultra-thinly traded micro cap Celyad ( CYAD +20.3% ) is up on almost a 10x surge in volume, albeit on turnover of only 26K shares, on the heels of its announcement of case data from a Phase 1 clinical trial, THINK , assessing lead CAR-T candidate CYAD-01 in patients with treatment-resis… read more...

Celyad up 20% on encouraging data on CAR-T candidate CYAD-01

via: SeekingAlpha at 2018-04-27 11:27:11:000

Ultra-thinly traded micro cap Celyad ( CYAD +20.3% ) is up on almost a 10x surge in volume, albeit on turnover of only 26K shares, on the heels of its announcement of case data from a Phase 1 clinical trial, THINK , assessing lead CAR-T candidate CYAD-01 in patients with treatment-resis… read more...

Celyad reports FY results

via: SeekingAlpha at 2018-03-22 16:20:44:000

Celyad (NASDAQ: CYAD ): FY GAAP EPS of -5.86 Revenue of3.5M (-58.9% Y/Y) Press Release More news on: Celyad, Earnings news and commentary, Healthcare stocks news, read more...

Celyad reports FY results

via: SeekingAlpha at 2018-03-22 16:20:44:000

Celyad (NASDAQ: CYAD ): FY GAAP EPS of -5.86 Revenue of3.5M (-58.9% Y/Y) Press Release More news on: Celyad, Earnings news and commentary, Healthcare stocks news, read more...

Celyad reports FY results

via: SeekingAlpha at 2018-03-22 16:20:44:000

Celyad (NASDAQ: CYAD ): FY GAAP EPS of -5.86 Revenue of3.5M (-58.9% Y/Y) Press Release More news on: Celyad, Earnings news and commentary, Healthcare stocks news, read more...

Celyad reports FY results

via: SeekingAlpha at 2018-03-22 16:20:44:000

Celyad (NASDAQ: CYAD ): FY GAAP EPS of -5.86 Revenue of3.5M (-58.9% Y/Y) Press Release More news on: Celyad, Earnings news and commentary, Healthcare stocks news, read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Celyad: Why Did It Go Down Recently?

via: SeekingAlpha at 2017-11-15 12:36:31:000

By Dr. Udaya K. Maiya, MBBS, MD, DNB, DCCF-PARIS In this piece, Dr Maiya follows up on his coverage on Celyad ( CYAD ), and discusses some data released from the THINK trial. Strategy The takeaway from the study data so far is that CYAD01 is active against AML, and has no safety conc… read more...

Will Biotech Continue To Boom?

via: SeekingAlpha at 2017-10-12 07:30:07:000

Will biotech stocks continue the run-up theyve enjoyed this year? Thats anyones guess. So far, in 2017, The SPDR S&P Biotech ETF ( XBI ) has soared 49% to its highest level in two years. On October 9th, Boris Schlossberg, Managing Director of FX Strategy for BK Asse… read more...

3 Things In Biotech You Should Learn Today: October 4, 2017

via: SeekingAlpha at 2017-10-04 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And today, I'd like to take a little experiment with the formatting for this edition, to get … read more...

Celyad reports 1H results

via: SeekingAlpha at 2017-08-29 02:04:55:000

Celyad (NASDAQ: CYAD ): 1H EPS of -1.52 More news on: Celyad, Earnings news and commentary, Healthcare stocks news, Read more … read more...

BioLife inks biopreservation media supply agreement with CAR-T developer Celyad

via: SeekingAlpha at 2017-07-31 07:23:04:000

BioLife Solutions (NASDAQ: BLFS ) closes a long-term agreement with Celyad (NASDAQ: CYAD ) to supply its clinical grade cell freeze media for use in latter's manufacturing process for its Natural Killer Receptor-based T-cell platform. More news on: BioLife Solutions, Inc., Celyad, Health… read more...

BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers

via: PR Newswire at 2017-07-31 06:30:00:000

BOTHELL, Wash. , July 31, 2017 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announ… read more...

Celyad: Some Questions For Management

via: SeekingAlpha at 2017-07-07 09:13:18:000

By Dr. Udaya K Maiya, MBBS, MD, DNB, DCCF-Paris I recently covered Celyad ( CYAD ), a small Belgian company developing CAR-T therapy for solid tumors, and I have a few follow up questions. Some of these needs to be answered by management, but some I could probably answer. First, a br… read more...

Gilead And CAR-T Of Solid Tumors: The Next Revolution In Cancer Therapeutics

via: SeekingAlpha at 2017-06-28 13:22:34:000

By Dr. Udaya K Maiya, MBBS, MD, DNB, DCCF-Paris In an earlier article I discussed Gileads ( GILD ) directionless onco-heme pipeline, and showed that the pipeline as it is now will never be able to replace its antiviral product assets. That assumed that Gilead has some semblanc… read more...

Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine's Next Frontier

via: SeekingAlpha at 2017-06-27 19:24:43:000

~ By Dr. Udaya Kumar Maiya, MBBS, MD, DNB, DCCF-Paris In the entire field of oncology, perhaps the most disruptive ongoing revolution is the application of Chimeric Antigen Receptor - T Cells or (CAR-T) to cancer immunotherapy. In this therapy, engineered T-cells that express a specific tum… read more...

TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come

via: SeekingAlpha at 2017-06-27 16:36:06:000

TiGenix ( TIG ) is a leading European biotech developing promising stem cell treatments. The biotechs most advanced product is Cx601 (Alofisel), a treatment for Crohns perianal fistulas which met its primary endpoint in a large Phase 3 trial, making it the first late… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX